Bruker Co. Forecasted to Earn Q2 2024 Earnings of $0.63 Per Share (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Zacks Research increased their Q2 2024 earnings per share (EPS) estimates for Bruker in a research report issued on Monday, September 11th. Zacks Research analyst M. Mondal now anticipates that the medical research company will post earnings of $0.63 per share for the quarter, up from their previous forecast of $0.62. The consensus estimate for Bruker’s current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Bruker’s FY2024 earnings at $2.85 EPS, Q2 2025 earnings at $0.76 EPS and FY2025 earnings at $3.10 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.02. The company had revenue of $681.90 million for the quarter, compared to analysts’ expectations of $647.82 million. Bruker had a return on equity of 33.24% and a net margin of 11.76%. Bruker’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the firm posted $0.45 EPS.

Separately, StockNews.com assumed coverage on shares of Bruker in a research report on Thursday, August 17th. They issued a “buy” rating on the stock. One analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.50.

Bruker Trading Up 3.2 %

Shares of BRKR traded up $1.95 during mid-day trading on Wednesday, reaching $63.71. The company’s stock had a trading volume of 201,134 shares, compared to its average volume of 810,950. Bruker has a 52 week low of $48.42 and a 52 week high of $84.84. The stock has a market cap of $9.36 billion, a PE ratio of 28.59, a P/E/G ratio of 1.33 and a beta of 1.13. The company’s fifty day moving average price is $68.05 and its two-hundred day moving average price is $72.87. The company has a current ratio of 2.08, a quick ratio of 1.21 and a debt-to-equity ratio of 0.90.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently bought and sold shares of BRKR. Tower Research Capital LLC TRC lifted its holdings in shares of Bruker by 31.8% during the first quarter. Tower Research Capital LLC TRC now owns 5,455 shares of the medical research company’s stock valued at $430,000 after purchasing an additional 1,316 shares during the last quarter. Signaturefd LLC boosted its holdings in Bruker by 19.2% in the first quarter. Signaturefd LLC now owns 889 shares of the medical research company’s stock worth $70,000 after acquiring an additional 143 shares in the last quarter. Treasurer of the State of North Carolina grew its stake in shares of Bruker by 0.7% in the first quarter. Treasurer of the State of North Carolina now owns 46,875 shares of the medical research company’s stock worth $3,696,000 after acquiring an additional 340 shares during the last quarter. HRT Financial LP bought a new position in shares of Bruker during the fourth quarter valued at $4,116,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Bruker by 10.5% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,063 shares of the medical research company’s stock worth $2,055,000 after purchasing an additional 2,470 shares during the last quarter. 79.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bruker

In related news, CFO Gerald N. Herman sold 14,242 shares of the firm’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $75.42, for a total value of $1,074,131.64. Following the sale, the chief financial officer now directly owns 36,462 shares of the company’s stock, valued at $2,749,964.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Bruker news, CEO Frank H. Laukien sold 37,947 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $64.81, for a total value of $2,459,345.07. Following the completion of the transaction, the chief executive officer now directly owns 38,217,344 shares in the company, valued at approximately $2,476,866,064.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gerald N. Herman sold 14,242 shares of Bruker stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $75.42, for a total transaction of $1,074,131.64. Following the sale, the chief financial officer now directly owns 36,462 shares in the company, valued at approximately $2,749,964.04. The disclosure for this sale can be found here. 28.20% of the stock is currently owned by company insiders.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, September 1st will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.31%. The ex-dividend date is Thursday, August 31st. Bruker’s payout ratio is 9.26%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies.